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Estrogens are required for the proliferation of hormone dependent breast cancer cells, making estrogen receptor (ER) positive
tumors amenable to endocrine therapies such as antiestrogens. However, resistance to these agents remains a significant cause of
treatment failure. We previously demonstrated that inactivation of the retinoblastoma protein (pRb) family tumor suppressors
causes antiestrogen resistance in MCF-7 cells, a widely studied model of estrogen responsive human breast cancers. In this study,
we investigate the mechanism by which pRb inactivation leads to antiestrogen resistance. Cdk4 and cdk2 are two key cell cycle
regulators that can phosphorylate and inactivate pRb, therefore we tested whether these kinases are required in cells lacking pRb
function. pRb family members were inactivated in MCF-7 cells by expressing polyomavirus large tumor antigen (PyLT), and cdk
activity was inhibited using the cdk inhibitors p16
INK4A and p21
Waf1/Cip1. Cdk4 activity was no longer required in cells lacking
functional pRb, while cdk2 activity was required for proliferation in both the presence and absence of pRb function. Using
inducible PyLTcelllines,wefurther demonstratedthatpRb inactivationleads toincreased cyclin A expression, cdk2activationand
proliferation in antiestrogen arrested cells. These results demonstrate that antiestrogens do not inhibit cdk2 activity or
proliferation of MCF-7 cells in the absence of pRb family function, and suggest that antiestrogen resistant breast cancer cells
resulting from pRb pathway inactivation would be susceptible to therapies that target cdk2.
Citation: Varma H, Skildum AJ, Conrad SE (2007) Functional Ablation of pRb Activates Cdk2 and Causes Antiestrogen Resistance in Human Breast
Cancer Cells. PLoS ONE 2(12): e1256. doi:10.1371/journal.pone.0001256
INTRODUCTION
Approximately 40 percent of human breast tumors depend on
estrogens for proliferation [1], and are therefore treated with drugs
such as antiestrogens and aromatase inhibitors, which target the
estrogen receptor (ER) [2]. While these therapies are very effective,
the development of resistance remains an important problem that
leads to relapse in many patients [2]. Multiple mechanisms have
been proposed to cause acquired antiestrogen resistance in breast
cancercells,butallofthesemechanismsmustultimatelyconvergeon
the cell cycle machinery since antiestrogens block proliferation of
these cells by affecting the cell cycle machinery [3].
Estrogens and antiestrogens control proliferation of breast cancer
cells by regulating the expression of multiple components of the cell
cycle machinery including cyclins D1 and A, cdc25a and the cyclin
dependent kinase inhibitors p21
Waf1/Cip1 (p21), and p27
Kip1 (p27)
[4,5,6]. These molecules regulate the activity of the cyclin dependent
kinases (cdks), cdk4 and cdk2, which in turn phosphorylate and
inactivate tumor suppressors of the retinoblastoma protein (pRb)
family [4]. The pRb family of proteins inhibit the G1 to S phase
transition by sequestering the E2F family of transcription factors [7].
The MCF-7 cell-line is the most widely studied model of
estrogen dependent and antiestrogen sensitive human breast
cancers [8]. MCF-7 cells were derived from a human tumor, they
are ER positive (ER
+), and their proliferation is stimulated by
estrogens and inhibited by antiestrogens in vivo and in vitro [9].
They contain wild type pRb [10], and estrogen treatment leads to
phosphorylation of pRb, cdk activation and progression into S
phase [5,11]. We previously investigated if pRb inactivation is
sufficient to cause antiestrogen resistance in MCF-7 cells by
expressing large tumor antigens (LT) of SV40 or Polyoma viruses,
which bind to and inactivate pRb family proteins. We found that
expression of either SV40 LT or Polyoma LT (PyLT) induced
proliferation of antiestrogen arrested MCF-7 cells, and that this
effect was dependent upon an intact pRb binding domain [12].
Furthermore, the ability of SV40 LT to overcome an antiestrogen-
induced cell cycle arrest resided within the N-terminal 259 amino
acids of the protein, excluding a role for p53 binding and a host of
other functions of this large multifunctional protein [12]. A recent
report using RNAi knockdown of pRb confirmed our results and
extended them to in vivo transplants in a murine model [13]. A loss
of pRb function occurs in a significant percentage (17 to 26
percent) of breast tumors [14,15,16], and together these results
suggest that ER+, pRb negative (pRb
-) tumors would respond
poorly to treatment with antiestrogens.
In this report, we investigate the mechanism(s) by which pRb
inactivation releases breast cancer cells from an antiestrogen-
induced cell cycle arrest. Estrogen treatment leads to the activation
of both cdk2 and cdk4 in breast cancer cell lines, and both of these
kinases can phosphorylate pRb [5,17]. We therefore investigated if
these kinases are required for proliferation of MCF-7 cells in the
absence of functional pRb family members. We demonstrate that
cdk4 activity is required for estrogen-induced proliferation in cells
with intact pRb function, but not when pRb family members are
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PLoS ONE | www.plosone.org 1 December 2007 | Issue 12 | e1256inactivated. In contrast, cdk2 activity is required irrespective of the
pRb status of cells. These results indicate that cdk4 is mainly
required for pRb inactivation, while cdk2 has additional targets
that are required for MCF-7 cell proliferation. We also
demonstrate that expression of PyLT leads to cdk2 activation,
even in the presence of antiestrogens. Together, our results
support a model in which cdk2 activation in response to estrogen
treatment is mediated, at least in part, via pRb inactivation. They
also suggest that cdk2, but not cdk4, might be a target for the
treatment of ER
+, pRb
2 tumors that are resistant to antiestrogens
or other endocrine treatments.
RESULTS
pRb inactivation by PyLT induces proliferation of
antiestrogen treated MCF-7 cells
Our previous results obtained with SV40 LT indicated that the
pRb binding domain of LT was required for conferring
antiestrogen resistance to MCF-7 cells [12]. To confirm that this
was also the case for PyLT, plasmids encoding wild type or a pRb
binding mutant of LT (Rb-LT) were transiently transfected into
MCF-7 cells. The cells were treated with antiestrogen ICI 182,780
(ICI) for 43 h to induce cell cycle arrest, and were then BrdU
labeled for an additional 5 h before fixation to assess the
percentage of cells that were actively synthesizing DNA. All
experiments were conducted in phenol red–free media supple-
mented with charcoal stripped serum (CSS), which is serum that is
depleted of estrogens [18]. The fixed cells were analyzed for PyLT
expression and BrdU incorporation by indirect immunofluores-
cence. Since, in transient transfection experiments only a certain
fraction of all cells take up transfected DNA and express detectable
levels of PyLT, the percentage of cells that were actively
synthesizing DNA was determined in both cells that expressed
PyLT (T
+) and those that did not (T
-) (Figure 1A, upper panel).
The results of this experiment confirmed that PyLT caused
antiestrogen resistant proliferation. Furthermore, the pRb binding
domain of PyLT was required for this effect, since the Rb-LT
mutant was unable to increase proliferation above the levels
observed in untransfected cells despite similar expression of the
wild type and mutant proteins (Figure 1A, lower panel).
We also considered using another estrogen responsive human
breast cancer cell line (ZR-75-1) for our experiments, but found
this cell line to be much less responsive to 17b-estradiol (E) and ICI
compared to the MCF-7 cells (Figure S1). These results are similar
to a previous report [19]. Since MCF-7 cells are the most widely
used experimental model to study the effects of E and ICI on
breast cancer proliferation, and results obtained in this cell line are
valid in clinical and in vivo models [8], we decided to use the MCF-
7 cells exclusively for further investigation.
PyLT-induced proliferation is sensitive to the cdk
inhibitor p21 but resistant to p16
INK4A
pRb is a physiological target of both cdk4 and cdk2 [17]. If the
primary function of one or both of these kinases in MCF-7 cells is
to phosphorylate pRb, then cells in which pRb family members
are inactivated by PyLT should no longer require the activity of
that kinase for proliferation. To test this possibility, MCF-7 cells
were transfected with PyLT alone, or together with vector (V),
p16
INK4A (p16) or p21 expression constructs (see Materials and
Methods for details about the constructs). p16 is a specific inhibitor
of cdk4, while p21 can inhibit both cdk2 and cdk4 but can also
facilitate cdk4-cyclin D complex formation [7,20]. The ability of
these cdk inhibitors to block PyLT-induced proliferation of ICI
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Figure 1. MCF-7 cells expressing PyLT are sensitive to p21 but
refractory to p16 arrest. (A) MCF-7 cells were transfected with wild
type PyLT or a Rb binding mutant (Rb-LT) of PyLT, treated with ICI in
media supplemented with charcoal stripped serum (CSS), and pro-
liferation was assayed by double indirect immunofluorescence for PyLT
and BrdU at 48 h post transfection (Materials and Methods). The
percentage of BrdU positive cells in PyLT expressing (T
+) and non-
expressing (T
-) cells is shown. The expression of wild type and mutant
PyLT in transfected cells was also assessed by immunoblotting (lower
panel, UT=untransfected control). (B) MCF-7 cells were cotransfected
with PyLT and either vector (V) alone, or p16/p21 encoding plasmids.
Proliferation in the presence of ICI was assayed by double indirect
immunofluorescence for PyLT and BrdU. Filled bars (T
+) represent
proliferation in cells expressing PyLT alone or along with vector, p16 or
p21. Empty bars (T
-) represent proliferation in cells that did not express
PyLT or PyLT and cotransfected plasmid constructs. (C) The Rb binding
mutant (Rb-LT) of PyLT was cotransfected with the above constructs in
cycling MCF-7 cells that were treated with E, and proliferation was
assayed as described above. All data shown in panels A–C is shown as
mean6S.E. of at least three independent experiments, with a minimum
of 100 PyLT positive and negative cells counted in each condition.
doi:10.1371/journal.pone.0001256.g001
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described above, and carrying out double indirect immunofluo-
rescence staining for PyLT and BrdU. In a control experiment,
Rb-LT was cotransfected with vector (V), p16 or p21 expression
constructs into E treated cells to determine if p16 or p21 inhibited
E-induced proliferation of MCF-7 in which pRb was functional.
Since in transient co-transfection experiments only a fraction of
the cells express the transfected genes, we assessed proliferation
both in cells that expressed LT (PyLT or Rb-LT) and the cdk
inhibitors (filled bars, T
+) and those that failed to express the
transfected genes (empty bars, T
-). The results shown in Figures 1B
and 1C indicate that cells transfected with the vector alone
exhibited a two-fold decrease in proliferation relative to untrans-
fected cells treated with E, or to those transfected with PyLT
alone. The reasons for the decreased proliferation in the vector-
transfected cells are not clear, however, the decreased proliferation
was not down to the levels in ICI-treated cells. The amount of
proliferation in vector co-transfected cells therefore served as the
baseline to assess the effects of p16 and p21 on PyLT-induced
proliferation. As shown in Figure 1B, p21 inhibited PyLT induced
proliferation in ICI-treated cells, while p16 did not. However, in
control co-transfections with Rb-LT, p16 inhibited E-induced
proliferation as efficiently as p21 as seen by decreased BrdU
incorporation in transfected cells (T
+) compared to cells that did
not express Rb-LT and p16 (T
-) (Figure 1C). These results
demonstrate that cdk4 activity is required in cells with intact pRb,
but not in cells where pRb has been inactivated. In contrast, cdk2
activity is required regardless of the pRb status of cells. They also
indicate that cdk4 is required mainly for pRb inactivation, while
cdk2 has targets in addition to pRb. Finally, they suggest that
antiestrogens do not inhibit cdk2 activity if pRb family members
have been inactivated.
Establishment of cell lines with inducible PyLT
expression
The results of the transient transfections described above indicated
that cdk2 activity is required for PyLT-induced proliferation of ICI
treated cells. To test if PyLT induces cdk2 activity, and to address
the mechanism of its induction, we established stable inducible cell
lines in which expression of PyLT was regulated by the addition of
a small molecule dimerizer, AP1510 (AP). The inducible
expression system and the selection of stable cell lines are
described in more detail in Materials and Methods. Briefly,
MCF-7 cells were transfected with a vector expressing PyLT from
an AP-inducible promoter, transfectants were selected with
hygromycin, and resistant clones were expanded into cell lines.
The resultant clonal cell lines were screened for PyLT expression
by Western blotting (Figure 2A), and several clones with low basal
and robust induced levels of PyLT (LT-5 and LT-6) were chosen
for further study. Expression of PyLT in the inducible cell lines
was also examined by immunofluorescence, and significant
variability in PyLT expression was observed in each clonal cell
line upon AP treatment, ranging from background to very high
levels (Figure 2B). Despite their clonal origin, only 50–60 percent
of the cells expressed detectable PyLT even in continued presence
of the selective agent. This variability in expression was observed
for all the clonal cell lines tested (data not shown).
PyLT induces cell cycle progression in ICI arrested
cells
The effects of PyLT expression on cell cycle progression after an
ICI-induced G1 arrest were assessed in two independent PyLT
inducible clones, LT-5 and LT-6 cells. LT-5 cells were pre-
arrested with ICI for 48 h, treated with E, ICI or ICI plus AP,
harvested at 12 h intervals, and analyzed by flow cytometry to
determine their cell cycle phase distribution. In ICI-treated
cultures, expression of PyLT increased the percentage of ICI
treated cells in S phase between 12 and 24 h, from 6–7 percent at
the 0 h time point to 20 percent by 24 h (Figure 3A, upper panel).
As expected, the percentage of cells in G1 decreased and those in
G2/M increased after PyLT induction (Figure 3A, lower panel). In
comparison, up to 40 percent of cells treated with E were in S
phase at the 24 h time point. Similar results were obtained with
the LT-6 clone (Figure S2). These experiments demonstrate that
though PyLT expression overcomes the cell cycle arrest of ICI
treated cells, it is not as effective as E treatment. This was in
contrast to the results in the transient transfection experiments
where PyLT was as effective as E (Figure 1A and 1C). Since
immunofluorescence staining indicated that only 50–60 percent of
stably transfected cells expressed detectable levels of PyLT after
AP treatment (Figure 2B), we hypothesized that the difference in
proliferation between cultures treated with E and ICI+AP might
be due to heterogeneous PyLT expression. We therefore analyzed
proliferation in high and low PyLT expressing LT-6 cells. Cells
were pre-arrested with ICI, then treated with ICI or E in the
presence of AP, labeled with BrdU, and fixed at 24 h. Cells were
stained for BrdU and PyLT, and the percentage of PyLT positive
and PyLT negative cells that were also BrdU positive was
determined. BrdU incorporation in cells with high PyLT
expression was similar to that in E treated cells (Figure 3B),
Figure 2. Selection of stable cell lines that express PyLT in an
inducible manner. (A) Clonal cell lines stably transfected with the
inducible PyLT construct were selected as described in Materials and
Methods, and screened for PyLT expression by immunoblotting after
24 h of AP treatment. Asterisk denotes PyLT clones 5 and 6 that were
chosen for further analysis based on robust induction. (B) One clonal
cell line (LT-6) was analyzed for PyLT expression by indirect
immunofluorescence. Micrographs show PyLT immunofluorescence in
the absence and presence of AP for 24 h, and a phase contrast picture
of the same field.
doi:10.1371/journal.pone.0001256.g002
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overcome an ICI-induced cell cycle arrest, and that the difference
seen between the E and ICI+AP treated samples in Figure 3A is
likely the result of sub-threshold PyLT expression in about half the
population of cells.
PyLT induces cyclin A and decreases p21 expression
To examine the effects of PyLT on the expression of proteins that
could contribute to antiestrogen resistance, LT-5 cells harvested in
parallel to those shown in Figure 3A were analyzed by
immunoblotting for PyLT and for cell cycle regulators including
cyclins A, E and D1, and the cdk inhibitors p21 and p27
(Figure 3C). A clear induction of PyLT was observed within
6 hours of AP addition, and high levels were maintained for the
duration of the experiment. In comparison with the ICI treated
cultures, there was no increase in cyclin D1 or cyclin E expression,
or a major decrease in p27 expression, in response to AP
treatment. However, there was an increase in cyclin A and
a decrease in p21 protein levels at the 24 and 36 h time points in
the ICI+AP treated cultures. These changes were also present and
of greater magnitude in the E-treated cultures, and correlated with
the increased percentage of cells in S phase at these time points.
Similar changes in cyclin A and p21 protein were confirmed in the
LT-6 clone (Figure S2). Both increased cyclin A and decreased p21
expression could contribute to cell cycle progression by increasing
cdk2 activity [7]. Decreases in cyclin E and cyclin D1 protein that
were observed at later time points in E-treated cells are likely
a result of cell cycle progression since these cyclins are known to be
degraded in late S phase [21,22] and this correlates with an
increase in the percentage of cells in S and G2/M (Figure 3A,
lower panel). A decrease in cyclin D1 was observed in ICI treated
cells and is likely due to the reported down regulation of cyclin D1
by ICI in MCF-7 cells [5,11].
PyLT induces cdk2 activity in ICI treated MCF-7 cells
To further examine the mechanism(s) by which PyLT induces
proliferation in ICI treated cells we carried out an extended time
course experiment. LT-6 cells were pre-arrested with ICI and then
treated with media containing estrogen-depleted serum (CSS), ICI
or E individually, or in combination with AP. Cells were harvested
at 24 h intervals for 4 to 5 days, and analyzed for cell cycle
distribution and protein expression. PyLT expression caused an
increase in the percentage of cells in S phase to a similar extent in
both the absence of E (CSS) and presence of ICI (Figure 4A). The
percentage of LT-6 cells in S phase was high in E treated cells and
was not substantially increased upon PyLT induction by AP
treatment. This indicates that PyLT is not able to further increase
proliferation in E treated cells, and that neither AP treatment nor
PyLT expression interferes with E stimulated proliferation. In all
treatments, two rounds of DNA synthesis can be clearly seen,
indicating that PyLT is able to promote antiestrogen resistant
proliferation for at least two cell cycles. We noted that progression
into the second cell cycle took longer than the first cell cycle. There
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Figure 3. Conditional PyLT expression induces cell cycle progression,
an increase in cyclin A and a decrease in p21 in ICI treated cells. (A)
LT-5 cells were growth arrested in ICI for 48 h, treated with ICI, E or
ICI+AP and then harvested at 12 h intervals. The cell cycle profile of
each sample was analyzed by flow cytometry, and the percentage of
cells in S phase is shown (top panel). The results represent the
average6S.D. of one experiment done in triplicate. The percentage of
cells in the different phases of the cell cycle is shown in a tabular format
(lower panel). The standard deviation was typically less than 2 percent.
Similar results were observed for the LT-6 clone (see Figure S2). (B) LT-6
cells were pre-arrested with ICI, treated with ICI+AP or E+AP for 24 h,
and BrdU was added to cultures during the final 5 h. Cells were then
fixed and stained for both PyLT and BrdU by double indirect
immunofluorescence. The percentage of PyLT positive (T
+) and negative
(T
2) cells that were also BrdU positive is shown. The results represent
the average6S.D. of one experiment done in triplicate with a 100 cells
r
counted per condition. (C) LT-5 cells were cultured, treated, and
harvested in parallel to those in (A) above. Cell extracts were prepared
and analyzed by western blotting for PyLT, cyclins A, E and D1 and the
cdk inhibitors p21 and p27. Actin was used as a loading control. Protein
levels were quantified by using the Image J software and these values
were normalized to actin and are shown below the respective blots. All
values are expressed relative to the zero time point that was arbitrarily
assigned a value of 1.
doi:10.1371/journal.pone.0001256.g003
Antiestrogen Resistance and Rb
PLoS ONE | www.plosone.org 4 December 2007 | Issue 12 | e1256are two potential contributors to this delay. First, antiestrogen
treatment of MCF-7 cells causes a cell cycle arrest in the early to
mid G1 [23]. Thus, cells released from an antiestrogen block (by E
or PyLT) would traverse from this point in G1 phase to S phase.
However to enter the S phase of second cell cycle, cells would take
additional time to traverse the G2/M phase of the first cell cycle,
and the complete G1 of the second cell cycle. A second contributor
could be that antiestrogen arrested cells are synchronized in G1
and they progress synchronously from G1 to S phase upon release
(by E or PyLT), but by the second cell cycle they enter S phase in
PyLT
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but substantially lower S phase peak of the second cell cycle and is
consistent with the cells entering the S phase over a prolonged
period of time.
Next we directly tested the effects of PyLT expression on cdk2
activity. In a parallel experiment to that described above, ICI
arrested cells were induced with AP, harvested at 24 h intervals for
4 days and subjected to western blotting and in vitro kinase assays for
cdk2 activity. ICI and E treated cells were harvested at 24 h, and
served as negative and positive controls, respectively. As shown in
Figure4B,cyclinAlevelspeakedat24and96 h,thetimepointswith
the highest percentage of cells in S phase. Cdk2 activity was highly
induced at 24 h in the ICI+AP treated cells compared to either the
0 h or the 24 h ICI treated time points (Figure 4C). However, E
treated cells had approximately two-fold higher cdk2 activity
(Figures 4C and 4D) at the 24 h time point than the ICI+AP
treated cells, which correlated with the increased percentage of cells
in S phase in these cultures (Figures 4A). Thus, PyLT expression
caused an increase in cdk2 activity that closely paralleled cyclin A
protein levels and S phase entry in ICI+AP treated MCF-7 cells.
DISCUSSION
We have demonstrated that expression of viral tumor antigens
(SV40 LT and PyLT) causes antiestrogen resistance in MCF-7
cells, and that the pRb binding and inactivation domain of these
proteins is required for this effect (Figure 1A) [12]. The viral LT
antigens are multifunctional proteins [24], and our results cannot
exclude the possibility that other functional domains contribute to
antiestrogen resistant proliferation. However, LT mutants that are
defective in p53 binding and truncation mutants (N terminal 1–
259 and 1–136 amino acids) that lack most functional domains
except the pRb inactivation domain, caused similar levels of
antiestrogen resistance as full length SV40 LT or PyLT ([12] and
data not shown). In addition, pRb knockdown using RNA
interference causes antiestrogen resistance in breast cancer cells
in vitro and in vivo [13,25]. Together these results indicate that pRb
inactivation is sufficient to cause antiestrogen resistance.
We have used the PyLT model to investigate the mechanisms
by which pRb inactivation alleviates an antiestrogen-induced cell
cycle arrest in MCF-7 cells. Both cdk4 and cdk2 activities are
regulated by estrogen and antiestrogens in these cells [5,11], and
both can phosphorylate pRb [17] . We therefore asked whether
the activity of both these kinases is required in the presence and
absence of functional pRb. Using the cdk inhibitors p16 (cdk4) and
p21 (cdk4 and cdk2), we confirmed that both cdk4 and cdk2 are
required for 17ß-estradiol’s proliferative effects in MCF-7 cells
with functional pRb (Figure 1C). However, in cells where PyLT
abrogated the pRb function, inhibition of cdk2 blocked proliferation
while inhibition of cdk4 had no effect (Figure 1B). These results are
consistent with a model in which the only requirement of cdk4 in
MCF-7 cell proliferation is to inactivate pRb family members
[26,27]. Although additional tissue specific roles for cdk4 have been
suggested [28], they do not appear to be required in this breast
cancer cell culture model. The results that cdk2 activity is induced
upon PyLT expression in ICI treated cells and cdk2 activity is
required even in the absence of functional pRb (Figure 4C), support
a model in which cdk2 is downstream of pRb and has additional
targets [27,29]. However, it is important to note that cdk2 is not
essential for all cell cycle progression, since genetic knockout of cdk2
does not prevent somatic cell proliferation in mice [30]. Further-
more, a requirement for cdk2 activity inviral tumor antigen-induced
proliferation is not universal, since both adenoviral E1A and SV40
LT were reported to overcome a cdk2 inhibitor (p27)-induced cell
cycle arrest without increasing cdk2 activity [31,32]. Although we
have not tested p27’s ability to inhibit proliferation in our study,
others have reported that p27 inhibits proliferation of MCF-7 cells
[4,6]. The differences observed between the various systems studied
couldbeduetodifferencesinoncoproteins,cdk2inhibitors,celltype,
or anti-proliferative signals (serum starvation versus antiestrogen
treatment) employed.
An important issue raised by our results is whether pRb
inactivation is sufficient to confer complete antiestrogen resistance.
In our inducible cell lines, expression of PyLT caused cell cycle
progression in ICI treated cells, but the maximum percentage of
cells in S phase was approximately two fold lower than in E treated
cells (Figure 3A and Figure S2). Similarly, cdk2 activity was highly
induced after PyLT induction, but only to approximately 50
percent of that seen in E treated cells (Figure 4D). A likely
explanation for at least part of the difference between ICI+AP and
E treated cells is heterogeneous PyLT expression, since only 50–60
percent cells in the inducible cell lines expressed detectable PyLT
upon AP induction (Figure 2B). When only cells expressing
detectable PyLT in the presence of ICI were scored for BrdU
incorporation, the percentage of positive cells was similar to that
seen in E treatments (Figure 3B). However, E has multiple targets
in MCF-7 cells, including c-myc, p21, and cdc25A [4,33,34,35].
Some of these targets may act independently of pRb [29], and
disruption of their regulation may be important for maximal cdk2
activation and proliferation in the presence of antiestrogens.
A final question is the mechanism by which pRb inactivation
leads to cdk activation and cell cycle progression in MCF-7 cells.
Cdk2 can associate with both cyclin E and cyclin A, and the
activity of both cyclin E/cdk2 and cyclin A/cdk2 complexes
increased after PyLT induction in ICI treated cells (data not
shown). Since the cyclin A promoter is regulated in an E2F
dependent manner [36], the release of E2F upon pRb inactivation
likely explains the increases in cyclin A expression (Figure 3C) and
cyclin A/cdk2 activity upon PyLT induction. The mechanism of
cyclin E/cdk2 activation is less clear, since cyclin E levels do not
increase after PyLT expression (Figure 3C). A small but
reproducible decrease in p21 expression was observed, which
could increase the number of active cyclin E/cdk2 complexes. In
addition, the formation of new cyclin A/cdk2 complexes could
titrate both p21 and p27 away from cyclin E/cdk2 complexes,
thereby leading to their activation [11].
In summary, these results support a model in which the
mitogenic effects of estrogen in breast cancer cells are largely
mediated by inactivation of pRb and/or related family members,
which in turn leads to cdk2 activation and cell cycle progression
pRb family
cdk2 activity 
G1- S phase transit
Estradiol
Figure 5. Model of E mediated proliferation of MCF-7 cells.
doi:10.1371/journal.pone.0001256.g005
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cdk2 activity or proliferation in the absence of pRb function
suggests that inhibition of cdk2 activity is critical to the antiproli-
ferative effects of antiestrogens, and this is supported by the fact that
loss of either p21 or p27 causes antiestrogen resistance [6]. The Rb
tumor suppressor gene is mutated in approximately 25 percent of
breast cancers, and a larger percentage show alterations in the pRb
pathway resulting from overexpression of cyclin D1 or loss of p16
[14,15]. Many of these pRb
2 tumors would likely express ER, and
would therefore be treated with compounds that target ER. Our
results suggest that such pRb
2,E R
+ tumors would be resistant to
such treatments, but would retain sensitivity to pharmacological
inhibitors of cdk2. These inhibitors of cdk2 that are in clinical trials
[37] are potential therapies for antiestrogen resistant breast cancers
with alterations in the pRb pathway.
MATERIALS AND METHODS
Cell culture
MCF-7cellswereobtainedfromtheDr.M.JohnsonattheLombardi
Cancer Center and ZR-75-1 cells were from the American Type
Culture Collection (Manassas, VA). These cells were routinely
maintained in IMEM (Biofluids) containing 5% fetal bovine serum
(FBS)(HyClone),penicillin(100units/ml)andstreptomycin(100 mg/
ml). Charcoal Stripped Serum (HyClone) containing media was used
for some experiments. Media for PyLT inducible clones also
contained hygromycin (10 mg/ml) plus G418 (50 mg/ml).
Cell cycle analysis
Cells were fixed, stained with propidium iodide, and analyzed with
a FACSVantage flow cytometer as previously described [33].
Plasmids and cloning
Plasmids encoding the wild type polyoma large T antigen (PyLT)
and pRb binding mutant (Rb-LT) were obtained from Dr. Brian
Schaffhausen (Tufts University, MA) [38]. A control plasmid
encoding green fluorescent protein (GFP) from a CMV promoter
(Vector) and the same vector encoding p16 and p21 as GFP fusion
proteins were obtained from Dr. Steve Weintraub (Washington
University, MO). For inducible expression, PyLT cDNA was
cloned into the pLH-Z12-I vector [33] in a two-step ligation. The
PyLT cDNA was excised from the pCMV PyLT vector using SalI
and BamHI and ligated into SalI and BamHI digested pIC19H
vector to generate pIC19H-PyLT. In the second step, the PyLT
cDNA was excised from pIC19H-PyLT using SalI (site was filled in
with nucleotides using T4 DNA polymerase to generate blunt
ends) and ClaI, and ligated into the polylinker region of pLH-Z12-
I that was digested with EcoRI (site filled in with nucleotides using
T4 DNA polymerase to generate blunt ends) and ClaI, to generate
pLH-Z12-PyLT, which was used for establishing stable cell lines.
Construction of stably transfected cell lines
expressing PyLT from an inducible promoter
A gene regulation system based on small molecule (AP1510)-
regulated protein dimerization has been previously described [33]
(www.ARIAD.com/regulationkits). The resultant clonal cell lines
were expanded and screened for inducible PyLT expression using
immunoblotting and indirect immunofluorescence.
Chemicals and Antibodies
Chemicals used were: ICI 182,780 (A. Wakeling, Zeneca
Pharmaceuticals); 17b-estradiol (E) (Sigma); 5-Bromo-29-deoxyur-
idine (BrdU) (Boehringer Mannheim); and AP1510 (ARIAD
Pharmaceuticals, Cambridge, MA). The rat polyclonal antibody
to PyLT that was used for immunoblotting was a gift of Dr.
Michele Fluck (Michigan State University, MI) and the rabbit
polyclonal antibody to cdk2 was a gift of Dr. Charles J. Sherr (St.
Jude Children’s Research Hospital, TN). Additional antibodies used
were: Anti-PyLT (Ab-1) rat monoclonal (Oncogene Science),
am o u s ea-BrdU antibody (Boehringer Mannheim) and FITC
conjugated goat anti-rat (Sigma chemicals). Antibodies to p21, p27,
actin and cyclins A, D and E, have been described previously [39].
Immunoblotting
Immunoblotting was performed as described previously [39].
Western blots were quantified using the Image J software (National
Institute of Health, Bethesda, MD).
Indirect Immunofluorescence
MCF-7 cells were transfected with either the PyLT plasmid alone
(0.3 mg) or in combination with 1 mg of pGFP (Vector), p16 or p21
as described previously [12] . After transfection, cells were treated
with medium containing 5% charcoal stripped serum (CSS) and
ICI (100 nM) and were labeled with 25 mM BrdU for 5 h before
fixation at 48 h post transfection. The double immunofluorescence
procedure for detecting transfected proteins and BrdU was
described previously [12]. BrdU incorporation was detected using
a mouse a-BrdU antibody [12]. PyLT was detected using the rat
monoclonal anti-PyLT (Ab-1) antibody (10 mg/ml in PBS)
followed by an FITC labeled goat anti-rat antibody (1:150
dilution in 1% BSA in PBS). The percentage of PyLT expressing
and non-expressing cells that were positive for BrdU was
determined, with a minimum of 100 cells being counted in each
condition per experiment. For the detection of PyLT expression in
PyLT stable inducible cell lines, cells were treated with AP
(300 nM) or vehicle and fixed 24 h after treatment. Immunoflu-
orescence for PyLT was performed as described above. For BrdU
incorporation in stable cell lines, cells were incubated in CSS+ICI
(100 nM) containing media for 2 days, and then transferred to
CSS+E (10 nM)+AP (300 nM) or CSS+ICI (100 nM)+AP
(300 nM) containing media. After 19 h the cells were labeled
with BrdU (25 mM) for 5 h, then fixed and analyzed by double
indirect immunofluorescence as described above.
Immunoprecipitations and kinase assays
Immunoprecipitations (IP) and cdk2 activity assays were per-
formed using a modification of a published method [40] as
described previously [35]. For IP experiments, 75 mg of total
cellular protein lysate was incubated with specific (anti-cdk2) or
control (normal goat IgG) antibodies. Kinase activity in the
resulting precipitates was measured using 2 mg Histone H1 (HH1)
substrate. Phosphorylated HH1 bands were quantified by
phosphorimager (Molecular Dynamics).
SUPPORTING INFORMATION
Figure S1 Relative estrogen and antiestrogen sensitivity of two
ER+ human breast cancer cell lines. MCF-7 and ZR-75-1 cells were
plated in regular growth medium for 24 h and then shifted to media
containing ICI (100 nM) or E (10 nM). Cells were harvested after
48 h and cell cycle analysis was performed as described in Materials
and Methods. The percentage of cells in S phase is shown from one
experiment performed in triplicate. Error bars represent 1 S.D.
Found at: doi:10.1371/journal.pone.0001256.s001 (0.65 MB EPS)
Figure S2 Conditional PyLT expression induces cell cycle
progression and an increase in cyclin A in the LT-6 clone. (A)
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PLoS ONE | www.plosone.org 7 December 2007 | Issue 12 | e1256LT-6 cells were growth arrested in ICI for 48 h, treated with
CSS+ICI, CSS+E or CSS+ICI+AP and then harvested at 12 h
intervals. The cell cycle profile of each sample was analyzed by
flow cytometry, and the percentage of cells in S phase is shown.
The results represent the average6S.D. of a single experiment
done in triplicate. (B) In parallel, cells were harvested for
immunoblotting and the levels of PyLT, cyclin A, p21 and actin
were determined. The western blots were quantified and
normalized to actin levels using Image J software. The zero h
time point was arbitrarily set as 1.
Found at: doi:10.1371/journal.pone.0001256.s002 (1.23 MB EPS)
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